SHR-7782 / Jiangsu Hengrui Pharma - LARVOL DELTA

A Trial of SHR-7782 for Treatment of Advanced Malignant Tumors (clinicaltrials.gov) - P1 | N=200 | Recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

A Trial of SHR-7782 for Treatment of Advanced Malignant Tumors (clinicaltrials.gov) - P1 | N=200 | Not yet recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

New P1 trial • Oncology • Solid Tumor

Hengrui Pharmaceuticals Gains NMPA Approval for SHR-7782 Clinical Trials in Advanced Solid Tumors (flcube.com) - "SHR-7782 injection is designed to specifically bind to antigens on the surface of tumor cells, enabling targeted tumor cell elimination."

New trial • Solid Tumor